Liposomal Bupivacaine vs Adductor Canal Block in Total Knee Arthroplasty
| Status: | Recruiting |
|---|---|
| Conditions: | Arthritis, Osteoarthritis (OA) |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 10/15/2017 |
| Start Date: | July 2016 |
| End Date: | June 2018 |
| Contact: | Andrea Torres, BS |
| Email: | atorres@txortho.com |
| Phone: | 512-439-1117 |
Patient Outcomes With Periarticular Liposomal Bupivacaine Injection vs Adductor Canal Block After Primary Total Knee Arthroplasty
This study is being done to evaluate the outcomes of patients undergoing total knee
replacement with two different methods of local pain control:shots of liposomal bupivacaine,
a long acting anesthetic, directly into the knee during surgery or anesthetic delivered
continuously to the adductor canal to provide long term pain relief. The goal is to try to
find a standard protocol that provides the greatest pain relief for patients undergoing total
knee replacement.
replacement with two different methods of local pain control:shots of liposomal bupivacaine,
a long acting anesthetic, directly into the knee during surgery or anesthetic delivered
continuously to the adductor canal to provide long term pain relief. The goal is to try to
find a standard protocol that provides the greatest pain relief for patients undergoing total
knee replacement.
Inclusion Criteria:
- Male or non-pregnant female between the ages of 18-65
- Patients willing and able to sign the informed consent
- Patients able to comply with follow-up requirements including self-evaluations
- Patients requiring a primary total knee replacement
- Patients with a diagnosis of osteoarthritis, traumatic arthritis, or avascular
necrosis
Exclusion Criteria:
- Revision total knee arthroplasty
- Bilateral total knee arthroplasty
- Patients with inflammatory arthritis
- Patients with a body mass index (BMI) > 40
- Allergy to ropivacaine, bupivacaine, or other local anesthetic agents
- Current use of opioid drugs
- Patients with a history of total or unicompartmental reconstruction of the affected
joint
- Patients that have had a high tibial osteotomy or femoral osteotomy
- Patients with neuromuscular or neurosensory deficiency, which would limit the ability
to assess pain levels
- Patients with a systemic or metabolic disorder leading to progressive bone
deterioration
- Patients that are immunologically compromised, or receiving chronic steroids (>30
days), excluding inhalers
- Patients' bone stock is compromised by disease or infection, which cannot provide
adequate support and/or fixation to the prosthesis
- Patients with knee fusion to the affected joint
- Patients with an active or suspected latent infection in or about the knee joint
- Patients that are prisoners
We found this trial at
1
site
Austin, Texas 78759
Principal Investigator: Tyler D Goldberg, MD
Phone: 512-439-1117
Click here to add this to my saved trials
